

Signer 3/10/06 4239-64111-05 497187 E-143-2002/0-US-03

**PATENT** Attorney Reference Number 4239-64111-05

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Martin et al.

**Application No. 10/519,311** Filed: December 22, 2004 Confirmation No. 9128

For: METHOD OF TREATING AUTOIMMUNE

DISEASES WITH INTERFERON-BETA

AND IL-2R ANTAGONIST

**Examiner:** Not yet assigned.

Art Unit: 1614

Attorney Reference No. 4239-64111-05

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

### **CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed March 10, 2006

### TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- $\boxtimes$ Supplemental Information Disclosure Statement Form 1449 and two references cited thereon
- $\boxtimes$ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- $\boxtimes$ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Susan Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

cc:

Docketing

SAS:dsh 03/10/06 4239-64111-05 497184 E-143-2002/0-US-03

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Martin et al.

Application No. 10/519,311 Filed: December 22, 2004 Confirmation No. 9128

For: METHOD OF TREATING

AUTOIMMUNE DISEASES WITH INTERFERON-BETA AND IL-2R

**ANTAGONIST** 

Examiner: Not yet assigned.

Art Unit: 1614

Attorney Reference No. 4239-64111-05

#### **CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)\_\_\_

Date Mailed March 10, 2006

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are two English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS.

However, if the Patent Office determines that a fee is required for Applicants to file this IDS,

Deposit Account authority is given on the enclosed transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Ву

Susan Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

SUPPLEMENTAL INFORMATION

SUPPLEMENTAL INFORMATION

BY APPLICANT

Attorney Docket Number	4239-64111-05
Application Number	10/519,311
Filing Date	December 22, 2004
First Named Inventor	Martin
Art Unit	1614
Examiner Name	Not yet assigned.

Examiner's Initials*	Cite No. (optional)		
		Becker et al. "Differential Gene Expression in Multiple Sclerosis Lesions Identified Using cDNA Microarrays," Poster Abstracts / J. Neuroimmunology 90:71 (1998) Abstract only	
		Sharief et al. "Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-β therapy," J. Neuroimmunology 129:224-231 (2002)	
·			
		,	
·			
<del> </del>			
eparati va			

SIGNATURE: CONSIDERED:	

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.